Brief: Nanovibronix Provides Business Update In Letter To Shareholders

ENvue Medical

15/11/2022 13:46

Nov 15 (Reuters) - Nanovibronix Inc  NAOV.O :
    * NANOVIBRONIX PROVIDES BUSINESS UPDATE IN LETTER TO
SHAREHOLDERS
    * NANOVIBRONIX INC - APPROVAL OF PAINSHIELD PLUS BY U.S.
FOOD AND
DRUG ADMINISTRATION (FDA) HAS BEEN SLOWER THAN WE HAD HOPED
    * NANOVIBRONIX INC - FOLLOWING SUBMISSION OF A SPECIAL 510K
APPLICATION ON PAINSHIELD PLUS, FDA ASKED FOR CLARIFICATIONS
    * NANOVIBRONIX INC - FDA REQUESTED THAT WE DISCONTINUE ANY
NEW
MARKETING OF OUR PAINSHIELD PLUS PRODUCTS UNTIL WE RECEIVE
FORMAL APPROVAL
    * NANOVIBRONIX INC - ENGAGED WITH TWO ENGINEERING FIRMS TO
ASSIST
WITH PREPARATION OF ADDITIONAL TEST DATA THAT WAS REQUESTED BY
FDA FOR PAINSHIELD PLUS
    * NANOVIBRONIX INC - CONTINUE TO BELIEVE THAT UPON APPROVAL,
PAINSHIELD PLUS WILL BE BACK ON TRACK AND INCREASE OUR REVENUE
FROM CERTAIN CHANNELS
    * NANOVIBRONIX INC - ANTICIPATE TWO ADDITIONAL STUDIES TO BE
INITIATED IN EARLY 2023 FOR UROSHIELD

Source text for Eikon:  ID:nBwcgVgtHa 
Further company coverage:  NAOV.O